Application and demonstration of bupivacaine liposomes in orthopedic hip operation ERAS

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500104528

Enrollment

Unknown

Registered

2025-06-18

Start date

2024-02-08

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Fracture

Interventions

Ropivacaine group:Ropivacaine iliofascial block

Bupivacaine liposomes group:Bupivacaine liposomes iliofascial block

Eligibility

Sex/Gender

All

Age

55 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Age: 50-85 years old; (2) American Society of Anesthesiologists (ASA) grading: I-III; (3) The patient intended to undergo hip surgery; (4) Normal coagulation function and platelet function; (5) <3h during operation; (6) The patient or family member agrees and signs the informed consent.

Exclusion criteria

Exclusion criteria: (1) Allergic to bupivacaine liposomes and other local anesthetics; (2) Puncture site infection, it is not appropriate to implement nerve block operators; (3) Pregnant or lactating patients; (4) opioid addicts; (5) Patients with severe consciousness disorder or mental system disease and cognitive dysfunction.

Design outcomes

Primary

Measure	Time frame
pain degree;Degree of motor block;Time to get out of bed after surgery;adverse reaction;	—

Secondary

Measure	Time frame
Time required for the first postoperative analgesic;Analgesic consumption;hospital stays;Functional recovery;	—

Countries

China

Contacts

Public ContactZhou Meiwu

Guiyang Second People's Hospital

80511920@qq.com+86 152 8606 5939

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026